BioSpace News Archive

New research from CSHL scientists suggests that cigarette smoke spurs the lungs to make more ACE2, the protein that the coronavirus responsible for COVID-19 grabs and uses to enter human cells.

Sophiris Bio Inc., announced that its board of directors has formally approved an immediate shutdown of the operations of the Company.

Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health, today announced the closing of its underwritten public offering of an aggregate of 12,650,000 shares of its common stock, including the full exercise of the underwriters’ option to purchase additional shares,

Clovis Oncology, Inc. announced that it has commenced an underwritten public offering of common stock.

Krystal Biotech, Inc. (Nasdaq: KRYS) (the “Company”), a gene therapy company developing a new class of transformative medicines to treat diseases caused by gene or protein dysfunction, today announced that it has commenced an underwritten public offering of its common stock

Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), today announced the appointment of Leopold Bertea, Ph.D., to the role of Senior Vice President of Technical Operations - Europe.

Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that its Board of Directors has appointed Michael J. MacCourt as the Company’s Chief Financial Officer, effective May 26, 2020.

Cabaletta Bio, Inc. (Nasdaq: CABA), today announced that in vivo data demonstrating specific engagement and elimination of anti-muscle-specific tyrosine kinase (MuSK) antibody-expressing target cells by Chimeric AutoAntibody Receptor (CAAR) T cells was presented at the American Academy of Neurology (AAN) 2020 Science Highlights Virtual Platform

Alcami, a North Carolina-based contract development and manufacturing organization, announced the appointment of Ken Domagalski and Elliott Franco to their Senior Leadership Team.

Krystal Biotech, Inc. (Nasdaq: KRYS) (the “Company”), a gene therapy company developing a new class of transformative medicines to treat diseases caused by gene or protein dysfunction, today announced that it has priced the previously announced underwritten public offering of 2,275,000 shares of its common stock, at a public offering price of $55.00 per share.